The instruction for medical use
of CEPPATATM medicine
A trade name
of CEPPATATM
the International unlicensed name
Is not present
the Dosage form
of the Tablet, coated, kishechnorastvorimy, 10 mg
Structure
One tablet contains
active agent of a serratiopeptidaz of 10 mg,
excipients: lactoses monohydrate, starch corn, magnesium a carbonate easy, sodium starch glikolit, magnesium stearate,
structure of a cover: a covering of Opadray of YS-1-7027 white (the titan dioxide, a gipromelloza, triacetin), Opadray of OY-P-7171 white (diethyl phthalate, the titan dioxide, stearic acid, polyvinyl acetate phthalate), the water purified, isopropyl alcohol, methylene dichloride.
The description
the Round, biconvex tablet covered with a kishechnorastvorimy cover of white color.
Pharmacotherapeutic group
Drugs for treatment of diseases of the musculoskeletal system others. Fermental drugs.
The ATX M09 AB code
passes the Pharmacological Pharmacokinetics Drug properties through a stomach in not changed look and is absorbed in intestines. The maximum concentration in plasma is reached by 1 hour of Serratiopeptidaz in insignificant quantity is defined in urine.
When assigning a therapeutic dose of a serratiopeptidaza it is not possible to study pharmacokinetics because of instability of enzyme in blood. Volunteers manage to study absorption when assigning high doses.
Serratiopeptidaza in plasma is defined after intake in a dosage of 100 mg/kg, the peak of its concentration is found in 30 min. and within 2 hours after reception, is soaked up in a small intestine and circulates in blood in the form of enzimopodobny active forms.
The pharmacodynamics
SerratyTM Active ingredient - the serratiopeptidaza allocated from a nonpathogenic colibacillus of Serratia E15 is proteolytic enzyme with fibrinolytic, anti-inflammatory and antiedematous activity.
Except reduction of inflammatory process SerrataTM weakens pain owing to blocking of release of mediators of pain from the inflammation center.
SerrataTM contacts in the ratio 1:1 alpha 2 - blood macroglobulin which masks its antigenicity, but keeps its enzymatic activity. Slowly passes into exudate in the place of inflammation, and gradually its level in blood decreases.
By means of hydrolysis of bradykinin, a histamine and serotonin of a serratiopeptidaz directly reduces dilatation of capillaries and their permeability. SerrataTM blocks plasmin inhibitors, promoting thus increase in fibrinolytic activity.
SerrataTM thanks to proteolysis of structural proteins of a phlegm improves rheological properties of a phlegm and promotes its otkhozhdeniye.
Indications
In complex therapy
- stretchings and ruptures of sheaves, changes and dislocations (for reduction of hypostasis and restoration of microcirculation in the place of damage)
- diseases of upper airways (for decrease in viscosity of a phlegm and simplification of its otkhozhdeniye)
- diseases of ENT organs: facilitates an otkhozhdeniye of a secretion of adnexal bosoms
- dermatitis with a pain syndrome
- mastitis (for resorption of hematomas, reduction of stagnation in mammary glands)
The route of administration and doses
Drug appoint as a part of complex therapy in a dose 10 mg (1 tablet) 2-3 times a day after a meal. It is necessary to swallow of tablets without chewing, washing down with 1 glass of water. Maximum single dose of 10 mg.
Maximum daily dose of 30 mg.
Duration of a course of treatment depends on character and dynamics of pathological process and is defined individually by the doctor.
Side effects
Seldom
- nausea
- vomiting
- anorexia
- discomfort in epigastriums
- diarrhea
Very seldom
- nasal bleeding
- a phlegm with blood impurity
- skin rashes, an itching, a dermahemia
- acute eosinophilic pneumonia
- at persons with individual intolerance to components of drug are possible reactions of hypersensitivity
of the Contraindication
- hypersensitivity to drug components
- a peptic ulcer of a stomach
- pregnancy and the period of a lactation
- children's and teenage age up to 18 years
For patients with disturbances of blood clotting, abnormal liver functions and the kidneys receiving anticoagulating treatment, when assigning a serratiopeptidaza it is necessary to provide careful observation.
Medicinal interactions
At simultaneous use drug strengthens effect of anticoagulants. The concomitant use of a serratiopeptidaza and carbamazepine leads to decrease in concentration in blood serum, therefore, to reduction of effect of carbamazepine
Special instructions
As drug influences blood clotting, it should be applied with care at patients with threat of bleeding and disturbance of time of blood clotting and also at patients who accept anticoagulants.
In case of a serious illness of a liver and kidneys, drug is used with care.
The drug should not be taken to patients with rare hereditary intolerance of a galactose, deficiency of Lapp lactase or malabsorption of glucose galactose.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
does not influence.
Overdose
Symptoms: nausea, vomiting, anorexia, discomfort in epigastriums, blood impurity in a phlegm and bleedings.
Treatment: symptomatic therapy.
A form of release and packing
On 10 tablets in planimetric bezjyacheykovy packing. One planimetric bezjyacheykovy packing together with the instruction for medical use in the state and Russian languages in cardboard packing. On 10 cardboard packs place in a box of cardboard (10х10).
On 30 tablets in planimetric bezjyacheykovy packing. On 1, 5 and 10 planimetric bezjyacheykovy packs together with the instruction for medical use in the state and Russian languages place in a cardboard box.
To Store storage conditions in the place protected from light, at a temperature not over 25C.
To store out of children's reach!
3 years
not to use a period of storage after the termination of the expiration date specified on packing.
Prescription status
According to the prescription
the Producer Kusum Heltker Pvt.
Ltd., JV 289 (A), Riiko Indl. Area, Chopanki, Bkhivadi (Raj.), India
Owner of the registration certificate
Kusum Heltker Pvt. Ltd., India
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods)
Representative office of Kusum Heltker Pvt Association. Ltd., India in RK
Almaty, Dostyk Ave, 117/6,
ph. / fax: 295-26-50, 295-26-55
of CEPPATATM medicine
A trade name
of CEPPATATM
the International unlicensed name
Is not present
the Dosage form
of the Tablet, coated, kishechnorastvorimy, 10 mg
Structure
One tablet contains
active agent of a serratiopeptidaz of 10 mg,
excipients: lactoses monohydrate, starch corn, magnesium a carbonate easy, sodium starch glikolit, magnesium stearate,
structure of a cover: a covering of Opadray of YS-1-7027 white (the titan dioxide, a gipromelloza, triacetin), Opadray of OY-P-7171 white (diethyl phthalate, the titan dioxide, stearic acid, polyvinyl acetate phthalate), the water purified, isopropyl alcohol, methylene dichloride.
The description
the Round, biconvex tablet covered with a kishechnorastvorimy cover of white color.
Pharmacotherapeutic group
Drugs for treatment of diseases of the musculoskeletal system others. Fermental drugs.
The ATX M09 AB code
passes the Pharmacological Pharmacokinetics Drug properties through a stomach in not changed look and is absorbed in intestines. The maximum concentration in plasma is reached by 1 hour of Serratiopeptidaz in insignificant quantity is defined in urine.
When assigning a therapeutic dose of a serratiopeptidaza it is not possible to study pharmacokinetics because of instability of enzyme in blood. Volunteers manage to study absorption when assigning high doses.
Serratiopeptidaza in plasma is defined after intake in a dosage of 100 mg/kg, the peak of its concentration is found in 30 min. and within 2 hours after reception, is soaked up in a small intestine and circulates in blood in the form of enzimopodobny active forms.
The pharmacodynamics
SerratyTM Active ingredient - the serratiopeptidaza allocated from a nonpathogenic colibacillus of Serratia E15 is proteolytic enzyme with fibrinolytic, anti-inflammatory and antiedematous activity.
Except reduction of inflammatory process SerrataTM weakens pain owing to blocking of release of mediators of pain from the inflammation center.
SerrataTM contacts in the ratio 1:1 alpha 2 - blood macroglobulin which masks its antigenicity, but keeps its enzymatic activity. Slowly passes into exudate in the place of inflammation, and gradually its level in blood decreases.
By means of hydrolysis of bradykinin, a histamine and serotonin of a serratiopeptidaz directly reduces dilatation of capillaries and their permeability. SerrataTM blocks plasmin inhibitors, promoting thus increase in fibrinolytic activity.
SerrataTM thanks to proteolysis of structural proteins of a phlegm improves rheological properties of a phlegm and promotes its otkhozhdeniye.
Indications
In complex therapy
- stretchings and ruptures of sheaves, changes and dislocations (for reduction of hypostasis and restoration of microcirculation in the place of damage)
- diseases of upper airways (for decrease in viscosity of a phlegm and simplification of its otkhozhdeniye)
- diseases of ENT organs: facilitates an otkhozhdeniye of a secretion of adnexal bosoms
- dermatitis with a pain syndrome
- mastitis (for resorption of hematomas, reduction of stagnation in mammary glands)
The route of administration and doses
Drug appoint as a part of complex therapy in a dose 10 mg (1 tablet) 2-3 times a day after a meal. It is necessary to swallow of tablets without chewing, washing down with 1 glass of water. Maximum single dose of 10 mg.
Maximum daily dose of 30 mg.
Duration of a course of treatment depends on character and dynamics of pathological process and is defined individually by the doctor.
Side effects
Seldom
- nausea
- vomiting
- anorexia
- discomfort in epigastriums
- diarrhea
Very seldom
- nasal bleeding
- a phlegm with blood impurity
- skin rashes, an itching, a dermahemia
- acute eosinophilic pneumonia
- at persons with individual intolerance to components of drug are possible reactions of hypersensitivity
of the Contraindication
- hypersensitivity to drug components
- a peptic ulcer of a stomach
- pregnancy and the period of a lactation
- children's and teenage age up to 18 years
For patients with disturbances of blood clotting, abnormal liver functions and the kidneys receiving anticoagulating treatment, when assigning a serratiopeptidaza it is necessary to provide careful observation.
Medicinal interactions
At simultaneous use drug strengthens effect of anticoagulants. The concomitant use of a serratiopeptidaza and carbamazepine leads to decrease in concentration in blood serum, therefore, to reduction of effect of carbamazepine
Special instructions
As drug influences blood clotting, it should be applied with care at patients with threat of bleeding and disturbance of time of blood clotting and also at patients who accept anticoagulants.
In case of a serious illness of a liver and kidneys, drug is used with care.
The drug should not be taken to patients with rare hereditary intolerance of a galactose, deficiency of Lapp lactase or malabsorption of glucose galactose.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
does not influence.
Overdose
Symptoms: nausea, vomiting, anorexia, discomfort in epigastriums, blood impurity in a phlegm and bleedings.
Treatment: symptomatic therapy.
A form of release and packing
On 10 tablets in planimetric bezjyacheykovy packing. One planimetric bezjyacheykovy packing together with the instruction for medical use in the state and Russian languages in cardboard packing. On 10 cardboard packs place in a box of cardboard (10х10).
On 30 tablets in planimetric bezjyacheykovy packing. On 1, 5 and 10 planimetric bezjyacheykovy packs together with the instruction for medical use in the state and Russian languages place in a cardboard box.
To Store storage conditions in the place protected from light, at a temperature not over 25C.
To store out of children's reach!
3 years
not to use a period of storage after the termination of the expiration date specified on packing.
Prescription status
According to the prescription
the Producer Kusum Heltker Pvt.
Ltd., JV 289 (A), Riiko Indl. Area, Chopanki, Bkhivadi (Raj.), India
Owner of the registration certificate
Kusum Heltker Pvt. Ltd., India
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods)
Representative office of Kusum Heltker Pvt Association. Ltd., India in RK
Almaty, Dostyk Ave, 117/6,
ph. / fax: 295-26-50, 295-26-55
Related Products
